OBJECTIVES: To examine the effect of raloxifene on bone turnover in elderly women. DESIGN: Clinical intervention. SETTING: Long-term care facilities. PARTICIPANTS: Nineteen women completed the study, mean age 85 (range 76-99). INTERVENTION: Raloxifene 60 mg was given daily for 12 weeks. MEASUREMENTS: Markers of bone turnover were plasma C-telopeptides of type I collagen (CTx), urine cross-linked N-telopeptides of type I collagen (NTx) and serum tartrate-resistant acid phosphatase (TRAP 5b), plasma osteocalcin, and serum bone alkaline phosphatase. Other markers were serum 25-OH vitamin D, parathyroid hormone, ionized calcium, and phosphate. Markers were measured at baseline, after calcium and vitamin D had been taken for 6 weeks, after raloxifene had been taken for 12 weeks, and 6 weeks after raloxifene had been stopped. Paired sample t test was used to examine changes in markers at each time point. RESULTS: Plasma CTx decreased on average by 31%, urinary NTx by 35%, plasma osteocalcin by 25%, serum bone alkaline phosphatase by 15% (P<.01), and serum TRAP 5b by 10% (P<.05) on treatment. CONCLUSION: Raloxifene reduces bone turnover in elderly women living in long-term care facilities. The effect of raloxifene on bone turnover is comparable with that seen in younger postmenopausal women.
OBJECTIVES: To examine the effect of raloxifene on bone turnover in elderly women. DESIGN: Clinical intervention. SETTING: Long-term care facilities. PARTICIPANTS: Nineteen women completed the study, mean age 85 (range 76-99). INTERVENTION: Raloxifene 60 mg was given daily for 12 weeks. MEASUREMENTS: Markers of bone turnover were plasma C-telopeptides of type I collagen (CTx), urine cross-linked N-telopeptides of type I collagen (NTx) and serum tartrate-resistant acid phosphatase (TRAP 5b), plasma osteocalcin, and serum bone alkaline phosphatase. Other markers were serum 25-OHvitamin D, parathyroid hormone, ionizedcalcium, and phosphate. Markers were measured at baseline, after calcium and vitamin D had been taken for 6 weeks, after raloxifene had been taken for 12 weeks, and 6 weeks after raloxifene had been stopped. Paired sample t test was used to examine changes in markers at each time point. RESULTS: Plasma CTx decreased on average by 31%, urinary NTx by 35%, plasma osteocalcin by 25%, serum bone alkaline phosphatase by 15% (P<.01), and serum TRAP 5b by 10% (P<.05) on treatment. CONCLUSION:Raloxifene reduces bone turnover in elderly women living in long-term care facilities. The effect of raloxifene on bone turnover is comparable with that seen in younger postmenopausal women.
Authors: C Colón-Emeric; K W Lyles; D A Levine; P House; A Schenck; J Gorospe; M Fermazin; K Oliver; J Alison; N Weisman; A Xie; J R Curtis; K Saag Journal: Osteoporos Int Date: 2006-11-21 Impact factor: 4.507
Authors: T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen Journal: Hum Genet Date: 2008-11-06 Impact factor: 4.132
Authors: Y Rolland; G Abellan van Kan; A Bénétos; H Blain; M Bonnefoy; P Chassagne; C Jeandel; M Laroche; F Nourhashémi; P Orcel; F Piette; C Ribot; P Ritz; C Roux; J Taillandier; F Trémollières; G Weryha; B Vellas Journal: J Nutr Health Aging Date: 2008-05 Impact factor: 4.075
Authors: D Miyaoka; Y Imanishi; M Ohara; N Hayashi; Y Nagata; S Yamada; K Mori; M Emoto; M Inaba Journal: Osteoporos Int Date: 2018-09-05 Impact factor: 4.507
Authors: P J Meunier; C Roux; S Ortolani; M Diaz-Curiel; J Compston; P Marquis; C Cormier; G Isaia; J Badurski; J D Wark; J Collette; J Y Reginster Journal: Osteoporos Int Date: 2009-01-20 Impact factor: 4.507